Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Binding, Competitive”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 739 records · Page 41Linked to original sources
PubMed1996

Inhibition of progesterone receptor activity in yeast by synthetic chemicals.

Numerous synthetic chemicals have estrogenic activity by interacting with the estrogen receptor. In this report, we test the hypothesis that some estrogenic chemicals may also modulate the human progesterone receptor (hPR) signaling pathway. This was evaluated by examining synthetic chemicals for their ability to modulate the activity of hPR expressed in yeast. The transcriptional activity of hPR was not increased in the presence of several synthetic chemicals. However, the estrogenic chemicals p-nonylphenol and 4-tert-octyphenol, and pentachlorophenol, effectively inhibited the activity of the hPR in yeast. Competition binding studies indicated these chemicals effectively competed with radiolabeled R5020, a synthetic progestin, for binding to the hPR in yeast. These results indicate that some synthetic chemicals directly inhibit the activity of hPR in yeast. The observations that some estrogenic chemicals can also inhibit hPR activity suggest a potential mechanism for the reported potent estrogenic activities of these chemicals.

Binding, Competitive↗
PubMed1994

Immunologic detection of the cellular receptor for urokinase plasminogen activator.

The cellular receptor for urokinase plasminogen activator (uPA-R) is a monomeric phosphatidylinositol-linked glycoprotein (gp40-65) that may contribute to the invasive capacity of tumor and inflammatory cells by focusing the activity of urokinase (uPA) in converting plasminogen to plasmin, a serine protease capable of degrading extracellular matrix proteins. The further characterization of uPA-R has been facilitated by our recent development of a monoclonal antibody, anti-Mo3f, specific for uPA-R. This mAb bound to uPA-R expressed by phorbol myristate acetate-stimulated U-937 cells and by NIH-3T3 cells permanently transfected with uPA-R cDNA. In competitive binding assays, anti-Mo3f inhibited the binding of fluorescein-conjugated uPA ligand to uPA-R expressed by U-937 cells and uPA-R transfectants; conversely, preexposure of cells to saturating quantities of exogenous uPA partially blocked the subsequent binding of anti-Mo3f mAb to uPA-R. Anti-Mo3f mAb was employed as the capture reagent in an ELISA for the quantitation of soluble forms of uPA-R (derived from U-937 cells and recombinant uPA-R) which had a sensitivity of approximately 4-12 ng/ml. Anti-Mo3f mAb was also applied as a serologic probe for the detection of uPA-R expressed by human tumor tissues. By immunoperoxidase staining, anti-Mo3f demonstrated positive tumor cell staining in 4 of 16 breast and 7 of 31 prostate carcinomas in formalin-fixed, paraffin-embedded specimens. These data indicate that the anti-Mo3f mAb detects an epitope proximate to or within the ligand binding domain (domain 1) of uPA-R and may be useful as a tool for the serologic detection of uPA-R in soluble form or associated with human tumors.

3T3 Cells↗
PubMed1995

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

Results of clinical trials have indicated that cA2, a neutralizing mouse/human IgG1 chimeric anti-human TNF-alpha monoclonal antibody, may have therapeutic benefit for rheumatoid arthritis patients. Arthritic joints contain, in addition to elevated levels of soluble TNF-alpha, high numbers of CD4+ T cells and macrophages, cells known to express transmembrane TNF-alpha upon activation. For that reason, we sought to determine if cA2 binds to transmembrane TNF-alpha and what effects such binding may have on TNF-alpha-expressing cells. A cell line expressing a cell-surface, mutant form of transmembrane TNF-alpha was prepared for these studies. Analysis of these TNF+ cells by flow cytometry, direct binding, and competitive binding assays showed that cA2 binds to the transmembrane form of TNF-alpha with high avidity. Binding of the IgG1 isotype of cA2, but not an IgG4 version of cA2, resulted in efficient killing of the TNF+ cells by both antibody-dependent cellular toxicity and complement-dependent cytotoxicity effector mechanisms. These findings indicate that, in addition to blocking soluble TNF-alpha activity, cA2 can bind to transmembrane TNF-alpha in vitro and suggest that cA2 binding may lead to lysis of TNF-alpha-expressing cells in vivo.

Animals↗
PubMed1995

Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors.

Two soluble receptors of tumour necrosis factor were evaluated for development as potential therapeutic agents for inflammatory disease. The recombinant human soluble Type I and Type II TNF receptors, rsTNF-RI and rsTNF-RII, were expressed at high levels in E. coli, refolded, and chromatographically purified to homogeneity. The potencies of both recombinant soluble receptors were similar to their naturally occurring soluble receptors. In in vitro cytotoxicity and competitive binding assays, both recombinant soluble receptors functioned to inhibit the biological effects of rhTNF-alpha although rsTNF-RI was a 5 to 30 fold more potent inhibitor of rhTNF-alpha than was rsTNF-RII or a truncated form of the soluble receptor, TNF-RII delta. In in vivo experiments in mice, rsTNF-RI was a better inhibitor than rsTNF-RII delta of rhTNF-alpha-stimulated changes in the percentages of circulating lymphocytes and neutrophils, influx of neutrophils into the peritoneal cavity, and serum IL-6 induction. At molar ratios of 0.1:1 and 0.01:1 (rsTNF-R:rhTNF-alpha), using the rsTNF-I or rsTNF-II delta, there was a trend towards enhancement of the induction of IL-6. However, higher ratios of either rsTNF-RI or rsTNF-RII delta significantly inhibited the rhTNF-alpha-stimulated increase in serum IL-6 levels. In a murine model of cytokine-induced shock, either rsTNF-RI or rsTNF-RII delta provided protection against the lethality of shock induced by a synergistic combination of rhTNF-alpha and rhIL-1 beta. Based on the results of these experiments, the rsTNF-RI was chosen as the better candidate for development as an anti-inflammatory agent.

Animals↗
PubMed1998

Homogeneous time-resolved IL-2-IL-2R alpha assay using fluorescence resonance energy transfer.

A homogeneous receptor-ligand assay based on fluorescence resonance energy transfer is described. In the assay, recombinant human interleukin 2 (IL-2) and a monoclonal antibody against the human IL-2 receptor alpha chain were labelled with a highly fluorescent europium chelate and Cy5, respectively. As a result of a successful receptor-ligand complex formation, these labels are brought into close proximity, which will thereby allow an energy transfer to occur from the donor (europium) to the acceptor (Cy5), upon excitation of the donor. Utilization of specific non-neutralizing antibodies made it possible to use crude hIL-2R alpha membranes prepared from recombinant baculovirus-infected Sf9 insect cells. The specific energy transfer was measured at the emission wavelength of Cy5 using a time-resolved fluorometer. The data presented, demonstrate that this assay design can be utilized for saturation as well as competitive binding experiments in addition to regular receptor titrations. As a rapid simple homogeneous assay it is particularily suitable for high throughput screening analyses.

Animals↗
PubMed1994

Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30).

Previous observations have demonstrated that monoclonal and polyclonal antibodies directed at SAG-1, the major surface protein of Toxoplasma gondii, decreased the number of T. gondii that infected fibroblast monolayers. Direct evaluation of parasite-host cell attachment using glutaraldehyde-fixed human fibroblasts and live tachyzoites was performed to determine whether SAG-1 was a ligand for the host cell receptor. The interaction between the fixed cells and T. gondii was specific and saturable as determined by a radioisotope competitive binding assay. Moreover, the specificity of this interaction was confirmed by comparison to another member of the Apicomplexa, Besnoitia jellisoni. Treatment of fresh extracellular T. gondii with rabbit polyclonal anti-SAG-1 serum inhibited parasite attachment to host cells by 71%. A monoclonal antibody (6A8) directed at SAG-1 was able to inhibit parasite binding to fixed host cells by 65%. Other mAb's directed at SAG-1 failed to inhibit parasite attachment in this assay. Fab derived from 6A8 mAb showed dose-dependent inhibition of parasite attachment. At an Fab concentration of 25 micrograms/ml, 47% inhibition was observed. Attachment assays using mutant parasites with defective SAG-1 (PTgA and PTgC) showed significantly reduced binding (26 and 39%) when compared to wild-type (SAG-1+) parentals. Taken together, these observations suggest that SAG-1 is an important parasite ligand that binds to the host cell in the process of T. gondii invasion.

Animals↗
PubMed1994

Effects of GnRH analogs on six ovarian cancer cell lines in culture.

The objective was to evaluate the possible direct anti-tumor effects of the GnRH agonists buserelin and leuprolide acetate and the GnRH antagonist antide on ovarian cancer cell lines in culture. Evidence from several hormone-responsive tumor systems suggests that GnRH analogs may have direct anti-tumor effects at the cellular level. In small clinical trials, the use of GnRH analogs in advanced refractory ovarian cancer has produced some dramatic responses. With this in mind, we evaluated the growth effects of the GnRH agonists buserelin and leuprolide and the GnRH antagonist antide over a range of concentrations on six established ovarian cancer cell lines over a period of 7 days. Cell viability was measured by an ATP-bioluminescence assay and expressed as a percentage of untreated control cultures. Analysis of variance was used to evaluate significant growth differences from control cultures. Although we were able to demonstrate statistically significant reduction in cell growth in two of six cell lines with buserelin, no dose-related response patterns were seen. While buserelin caused a maximum 16% inhibition of growth, antide had no effect on tumor growth at the same doses. Leuprolide acetate produced significant dose-dependent inhibition of growth in all six cell lines when doses were increased to supraphysiologic levels, but demonstrated no significant inhibition at doses that are clinically attainable. Furthermore, competitive binding assays showed no specific GnRH binding in any of the six ovarian cell lines tested. Although GnRH analogs have growth inhibitory effects on ovarian cancer cells in vitro, the magnitude of this effect at doses that are clinically achievable is insufficient to support direct tumor effects as the mechanism behind the clinical responses reported.

Analysis of Variance↗
PubMed1996

Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors.

Type-II diabetes is a risk factor for pancreatic cancer. In addition, diabetic patients present with more advanced tumors and have shortened survival compared to stage-matched counterparts. We hypothesize that the diabetic endocrine milieu, particularly elevated plasma insulin, favors pancreatic cancer growth. This study examines six human pancreatic cancer cell lines for the presence of insulin receptors and the influence of insulin on tumor proliferation. Classical competitive binding assays are performed using [125I insulin. Cell proliferation assays are conducted over 3 days on cultured cell lines (n = 6 replicates) with increasing concentrations of insulin. Insulin receptors are demonstrated on all six cell lines and dose dependent increases in cell proliferation (15-120% of control) are demonstrated in response to insulin. Patients with type-II diabetes hypersecrete insulin. The presence of high-affinity insulin receptors and dose dependent increases in pancreatic cancer cell proliferation with insulin supports the hypothesis that insulin may be an important tumor growth promoter in diabetes, particularly if paracrine mechanisms are involved. Additional study is required to determine whether other islet peptides altered in diabetes influence tumor growth and whether elevated plasma insulin favors pancreatic cancer induction.

Adenocarcinoma↗
PubMed2000

High-level secretion of biologically active recombinant human macrophage inflammatory protein-1alpha by the methylotrophic yeast Pichia pastoris.

The human CC chemokine macrophage inflammatory protein-1alpha (MIP-1alpha) was produced at a high level in Pichia pastoris under transcriptional control of the highly inducible alcohol oxidase 1 promoter. To ensure proper folding and secretion of the recombinant polypeptide, the MIP-1alpha gene had been fused to the Saccharomyces cerevisiae alpha-factor prepropeptide. As was revealed by analysis of the cell culture supernatant of recombinant Pichia pastoris, MIP-1alpha was efficiently secreted. Immunoblot analysis of secreted proteins from recombinant clones using a polyclonal antibody directed against MIP-1alpha revealed an apparent molecular mass of 8 kDa for the recombinant polypeptide. Up to 70 mg of MIP-1alpha was purified from 1 liter of yeast culture supernatant by a single chromatography step. Biological activity of recombinant MIP-1alpha was shown in a chemotaxis assay. Here, the polypeptide specifically induced migration of U937 cells expressing the CCR1 (MIP-1alpha receptor). Also, in competition binding assays the recombinant MIP-1alpha displayed high affinity binding.

Amino Acid Sequence↗
PubMed1994

Investigation of antiestrogenic properties of unleaded gasoline in female mice.

Chronic exposure of female B6C3F1 mice to a high concentration of unleaded gasoline (UG) vapor induced liver tumors and caused uterine changes suggestive of estrogen antagonism. These effects of UG may be related, since estrogens inhibit hepatocarcinogenesis in mice. The purpose of this study was to determine if antiestrogenic properties of UG could be demonstrated in sensitive short-term assays. Competitive binding to estrogen receptors was assayed in vitro in uterine cytosols prepared from ovariectomized (OVEX) mice. UG did not inhibit specific binding of 17 beta-[3H]estradiol (E2) to uterine cytosols. To determine if UG induced estrogen metabolism, hepatocyte suspensions were prepared from female mice treated by intragastric intubation (ig) for 3 days with corn oil (control) or UG (1800 mg/kg/day). In a quantitative in vitro assay, hepatocytes isolated from UG-treated mice converted E2 and 17 alpha-ethinyl estradiol to water soluble metabolites at a three-fold faster rate than control hepatocytes. Dose-response studies confirmed the induction of E2 metabolism by UG doses as low as 600 mg/kg/day. In a 3-day uterotrophic assay, immature female mice cotreated with UG (600 or 1800 mg/kg/day, ig) and E2 (1 microgram/day, sc) had similar relative uterus weights and uterine peroxidase activity as mice cotreated with corn oil and E2. In a modified uterotrophic assay, OVEX mice treated with corn oil or UG (2400 mg/kg/day, ig) on Days 1-4 and cotreated with E2 (4 micrograms/kg/day, sc) on Days 3-4 had similar uterus weights on Day 5. Thus, while ig treatment of mice with UG induced estrogen metabolism in isolated hepatocytes, this induction did not have functional antiestrogenic consequences as measured by uterotrophic assays. These data suggest that the uterine effects caused by chronic exposure of mice to UG vapor may not be due to direct antiestrogenic effects of UG.

Animals↗
PubMed1997

Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Cannabinoid receptor (CB) expression was characterized in immunological cell and tissue preparations. Northern analysis revealed approximately 6-kb transcripts for CB1 (brain-type) in mouse spleen and brain and in rat cerebellum. CB1 was not detected in mouse thymus or rat spleen RNA by Northern analysis. CB2 (peripheral) was detected as a approximately 4-kb transcript in mouse spleen and thymus and as approximately 2.4-kb transcripts in rat spleen. Quantitation of CB2 transcripts in mouse spleen and thymus revealed approximately 4 x 10(3) and approximately 4 x 10(2) molecules/100 ng RNA, respectively, with no quantifiable CB2 in mouse brain. Conversely, CB1 was expressed in mouse brain (approximately 2 x 10(5) molecules/100 ng RNA) with lower expression in mouse spleen (approximately 2 x 10(2) molecules/100 ng RNA) and was not quantifiable in mouse thymus. Competition binding in intact mouse splenocytes demonstrated that nonradiolabeled cannabinoids CP-55940, Win-55212-2, CP-56667, delta 9-THC, and cannabinol all competed for receptor binding with 3H-CP-55940, a high-affinity nondiscriminating CB1 and CB2 receptor ligand. Based on previous findings which demonstrated a marked inhibition of T-cell-dependent immune responses by cannabinoids, primary T cells and several T-cell lines were characterized. Radioligand binding analysis identified 100-300 cannabinoid receptor binding sites/cell with an approximate Kd of 200-700 pM in purified splenic T cells which also exhibited cannabinoid-induced inhibition of adenylate cyclase. Northern analysis of human T-cell lines revealed approximately 2.4-kb CB2 mRNA transcripts but no CB1 in HPB-ALL cells, a cell line which also exhibited inhibition of adenylate cyclase by delta 9-THC. Conversely, Jurkat E6-1 cells expressed an unusual mRNA banding pattern for CB2 expressing three distinct transcript sizes, none of which were 2.4 kb, the size for human CB2. Jurkat also did not express CB1 mRNA and did not exhibit inhibition of adenylate cyclase when treated with delta 9-THC. Collectively, these results provide further evidence that CB2 is the predominant cannabinoid receptor within the immune system and that this form of the receptor is expressed on T cells.

Adenylyl Cyclases↗
PubMed1995

Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17.

Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17 (BTV-17) were investigated with a panel of five neutralizing monoclonal antibodies (MAbs). One MAb (MAb 034) was originally raised to BTV serotype 10 (BTV-10) but also neutralizes BTV-17 (P. V. Rossitto, and N. J. MacLachlan, 1992, J. Gen. Virol. 73, 1947-1952). Competitive binding studies indicate that the MAbs recognize at least two epitopes on the neutralizing outer capsid protein VP2 of BTV-17. The MAbs were used to select neutralization-resistant variant [escape mutant (EM)] viruses and to determine the phenotypic characteristics of these EM viruses by immunoprecipitation and neutralization assays. Sequencing of the L2 gene, which encodes VP2, identified mutations responsible for the altered phenotypic properties exhibited by each EM virus. Four amino acids in three regions of VP2 are critical to the expression of the epitopes recognized by the panel of neutralizing MAbs. Amino acid 199 affects the binding of MAbs 17.82, 17.83, and 17.813; amino acid 213 affects the binding of MAb 17.85; and amino acids 327 and 582 synergistically affect the binding of MAb 034. Similarly, amino acids 327 and 402 synergistically affect the binding of MAb 034 to BTV-10 (C. D. DeMaula, H. W. Heidner, P. V. Rossitto, C. M. Pierce, and N. J. MacLachlan, 1993, Virology 195, 292-296), suggesting that the neutralizing epitope common to BTV-10 and BTV-17 has a similar location in VP2 of these two antigenically distinct viruses.

Animals↗
PubMed2001

Monoclonal antibodies against different epitopes of nonstructural protein sigmaNS of avian reovirus S1133.

Ten monoclonal antibodies (MAbs) were prepared against the nonstructural protein sigmaNS of avian reovirus S1133. Eight of them were selected for two-way competitive binding assay after coupling with horseradish peroxidase. The results allowed the definition of three epitopes, designated A, B, and C. Blocking assay of poly(A)-Sepharose binding activity of sigmaNS with MAbs indicated that MAb recognizing epitope B was able to block poly(A) oligomer binding, suggesting that epitope B is involved in ssRNA binding of sigmaNS. An immuno-dot binding assay was used to analyze the effect of denaturation on antibody recognition of the epitopes. All MAbs bound to protein sigmaNS in its native form. After denaturation by boiling in SDS and 2-mercaptoethanol, the binding of MAbs recognizing epitopes B and C was not affected. The reactivity of MAbs recognizing epitope A was fully abolished by denaturation. These results suggest that the binding of MAbs directed against epitope A is conformation-dependent; however, the recognition by MAbs of epitopes B and C is not conformation-dependent. In addition, the results from the cross-reactivity of MAbs to heterologous avian reovirus strains suggest that the three epitopes are highly conserved among these virus strains.

Animals↗
PubMed1975

Immunochemical and compositional comparison of cytochrome P-450 cam of Pseudomonas putida and P-450 lm of phenobarbital-induced rabbit liver microsomes.

Although highly purified cytochrome P-450 of Pseudomonas putida (P-450 cam), and that from phenobarbital-induced rabbit liver microsomes (P-450 LM), differ markedly in their catalytic and physical properties, they show immunological cross reaction by competitive binding and inhibition of catalytic activity, and are of similar amino acid composition. Upon treatment with cyanogen bromide they yield small heme-containing peptides of highly similar amino acid composition.

Amino Acids↗
PubMed1990

Topological and functional analysis of epitopes on the S(E2) and HE(E3) glycoproteins of bovine enteric coronavirus.

Monoclonal antibodies (Mabs) were selected which reacted with bovine enteric coronavirus S and HE. Mabs to S were used to identify 2 cleavage products of S, S/gp105 and S/gp90. Monoclonals to S/gp105 and HE neutralised the virus; only Mabs to the latter inhibited haemagglutination and acetyl-esterase activity. Topological distribution of epitopes was studied on these 3 glycoproteins by means of competition binding experiments. Two independent epitopes were characterised on HE, 4 on S/gp105, and 2 on S/gp90. Neutralising Mabs defined one major site on both S/gp105 and HE; however a minor neutralisation epitope was also delineated on S/gp105. Functional mapping using neutralisation-resistant mutants confirmed the topological distribution of epitopes on S/gp105.

Animals↗
PubMed1996

Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing.

In this study, we characterized the interactions of arbutamine, a novel catecholamine developed for use as a cardiac stress testing agent, with different adrenergic receptor subtypes in vitro. These effects were compared with those of isoproterenol. In the electrically stimulated left atria of rats, arbutamine increased contractile force. The pD2 values (- log of the dose that produces 50% of the maximal responses) for arbutamine and isoproterenol were 8.45 +/- 0.15 and 8.55 +/- 0.02, respectively. Metoprolol shifted the concentration-effect curves for both isoproterenol and arbutamine to the right with a pA2 value (- log of the dose of the antagonist that reduces the maximal responses of an agonist to 50%) of 7.22-7.5. Both arbutamine and isoproterenol increased the rate of spontaneously beating rat right atria with pD2 values of 9.0 +/- 0.19 and 8.82 +/- 0.18, respectively. The affinity constants (KA) of arbutamine and isoproterenol for cardiac beta1-adrenergic receptors, as determined by competition binding assays, were found to be 7.32 and 6.04, respectively. In guinea pig trachea, arbutamine and isoproterenol produced a concentration-dependent relaxation that was blocked by propranolol. Their pD2 values were 7.9 +/- 0.1 and 8.2 +/- 0.1, respectively. Arbutamine contracted isolated rat aortic rings with a maximal increase of 38.1 +/- 6.7% that of 10 microM of norepinephrine. In rat white adipocytes, arbutamine, isoproterenol, and BRL-37344 stimulated glycerol release, with the order of potency being BRL-37344 > arbutamine > isoproterenol. In hamster brown adipocytes, the order was arbutamine > isoproterenol > BRL-37344. Moreover, arbutamine stimulated beta3-adrenergic receptors in guinea pig ileum. In conclusion, arbutamine is a novel catecholamine with similar potency and efficacy to that of isoproterenol. It stimulates cardiac beta1-, tracheal beta2-, and adiopocyte beta3-adrenergic receptors. Arbutamine does not stimulate alpha-adrenergic receptors at concentrations that were high enough to maximally activate the beta-adrenergic receptors.

Adipocytes↗
PubMed1975

Corticoid uptake by the paraventricular nucleus in the hypothalamus of the duck, Anas platyrhynchos.

3H-corticoids were localized by autoradiography in small neurons in the area of the magnocellular paraventricular nucleus of mallard ducks. Correlative data show that: (1) the label is principally unmetabolized steroid, (2) the hypothalamus competitively binds corticosterone, (3) the paraventricular nucleus contains immunoreactive neurophysin, is richly innervated by boutons of monoaminergic nerves and is involved in the adaptive response to osmotic stress.

Adrenal Cortex Hormones↗
PubMed1987

Inhibition of the catalytic properties of Staphylococcus aureus nuclease by monoclonal antibodies.

Monoclonal antibodies (Mab) specific for Staphylococcus aureus nuclease (nuclease) were examined for their capacity to inhibit the enzyme-mediated cleavage of DNA. Within a panel of 22 anti-nuclease Mab produced by hybridoma cell lines derived from SJL/J, A/J or BALB/c mice, only five were capable of modifying nuclease activity. Of the five, only one protected DNA from enzymatic degradation whereas the others reduced the rate of the enzymatic reaction. When mixed together, partially inactivating Mabs were frequently more efficient inhibitors than when used individually. It was shown by competitive binding assay that nuclease could be bound simultaneously to more than one Mab. Mixtures of five inactivating Mabs were able to completely block the nuclease activity. Although the actual mechanism for Mab nuclease inactivation is not known, the present data are consistent with simple steric hindrance for the formation of the DNA-nuclease complex by bulky Mab molecules bound to epitopes close to, but distinct from, nuclease catalytic sites. A mathematical model for Mab binding and inactivation of nuclease, taking into account multiple binding events for one or two Mabs interacting with nuclease, was used to derive affinities and maximum reductions of the enzymatic rate (details on the derivation of the equations and on the hypotheses of the model are given in an appendix). This analysis showed that the observed cooperative effects were dependent on the formation of multi-molecular complexes in which nuclease is bound simultaneously to two (or more) different Mabs. It also shows that the formation of cyclic complexes, if allowed, might result in very high apparent affinities. Since in screening of hybridoma fusions, the probability of finding such pairs of monoclonal antibodies would be low, this phenomenon may explain the fact that no Mab, or mixture of Mabs, matched the polyclonal antisera in capacity to block nuclease enzymatic activity.

Antibodies, Monoclonal↗